TCF7 and neoplasm: TCF7+PD-1+ TILs mediated the proliferative response to immunotherapy, generating both TCF7+PD-1+ and differentiated TCF7-PD-1+ cells. Human TCF7+PD-1+ cells were detected among tumor-reactive CD8+ T cells in the blood and tumor.